NYSE:GMED - Globus Medical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $50.33 -1.43 (-2.76 %) (As of 11/20/2018 06:39 AM ET)Previous Close$51.76Today's Range$49.24 - $52.0952-Week Range$36.27 - $57.83Volume659,958 shsAverage Volume767,987 shsMarket Capitalization$5.10 billionP/E Ratio38.42Dividend YieldN/ABeta0.65 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address an array of spinal pathologies, anatomies, and surgical approaches. Its fusion products include a range of implant and surgical approach options to treat degenerative, deformity, tumor, and trauma conditions along the spine from the occiput to the sacrum. The company's disruptive technology products comprise products that allow for minimally invasive surgical techniques; and new treatment alternatives, including imaging, navigational, and robotic technologies, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous process spacer products. Its disruptive technology products also consist of regenerative biologics products, including bioactive glass-based bone void fillers and ceramic-collagen for pelvic/extremity and posterolateral spinal fusion procedures; and interventional pain management solutions, which comprise treatments for vertebral compression fractures. In addition, the company offers products for the treatment of orthopedic trauma, including compression screws, fixation plates, intramedullary nails, and external fixation systems. Further, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania. Receive GMED News and Ratings via Email Sign-up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:GMED Previous Symbol CUSIP37957720 Webwww.globusmedical.com Phone610-930-1800 Debt Debt-to-Equity RatioN/A Current Ratio7.91 Quick Ratio6.39 Price-To-Earnings Trailing P/E Ratio38.42 Forward P/E Ratio31.07 P/E Growth2.49 Sales & Book Value Annual Sales$635.98 million Price / Sales7.79 Cash Flow$1.7439 per share Price / Cash28.86 Book Value$10.01 per share Price / Book5.03 Profitability EPS (Most Recent Fiscal Year)$1.31 Net Income$107.34 million Net Margins20.79% Return on Equity15.36% Return on Assets14.02% Miscellaneous Employees1,500 Outstanding Shares98,480,000Market Cap$5.10 billion OptionableOptionable Globus Medical (NYSE:GMED) Frequently Asked Questions What is Globus Medical's stock symbol? Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED." How were Globus Medical's earnings last quarter? Globus Medical Inc (NYSE:GMED) posted its earnings results on Thursday, November, 8th. The medical device company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.33 by $0.06. The medical device company had revenue of $169.20 million for the quarter, compared to analysts' expectations of $167.47 million. Globus Medical had a net margin of 20.79% and a return on equity of 15.36%. The company's revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.30 earnings per share. View Globus Medical's Earnings History. When is Globus Medical's next earnings date? Globus Medical is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for Globus Medical. What guidance has Globus Medical issued on next quarter's earnings? Globus Medical updated its FY18 earnings guidance on Thursday, November, 8th. The company provided EPS guidance of $1.62 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.55. The company issued revenue guidance of $705 million, compared to the consensus revenue estimate of $701.45 million.Globus Medical also updated its FY 2018 guidance to $1.62-1.62 EPS. What price target have analysts set for GMED? 11 analysts have issued 12-month price targets for Globus Medical's shares. Their forecasts range from $36.00 to $65.00. On average, they anticipate Globus Medical's stock price to reach $55.8182 in the next twelve months. This suggests a possible upside of 10.9% from the stock's current price. View Analyst Price Targets for Globus Medical. What is the consensus analysts' recommendation for Globus Medical? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 2 sell ratings, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Globus Medical. Has Globus Medical been receiving favorable news coverage? Headlines about GMED stock have trended somewhat positive recently, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Globus Medical earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave news coverage about the medical device company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Globus Medical's key competitors? Some companies that are related to Globus Medical include ResMed (RMD), ABIOMED (ABMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Haemonetics (HAE), ICU Medical (ICUI), Insulet (PODD), Penumbra (PEN), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Novocure (NVCR) and Glaukos (GKOS). Who are Globus Medical's key executives? Globus Medical's management team includes the folowing people: Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 51)Mr. David M. Demski, CEO & Director (Age 60)Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 47)Mr. David D. Davidar, Co-Founder & Director (Age 52)Mr. Daniel T. Scavilla, CFO, Exec. VP & Chief Commercial Officer (Age 53) Who are Globus Medical's major shareholders? Globus Medical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.62%), AQR Capital Management LLC (2.44%), Bank of New York Mellon Corp (1.63%), Janus Henderson Group PLC (1.40%), The Manufacturers Life Insurance Company (1.36%) and Van Berkom & Associates Inc. (1.26%). Company insiders that own Globus Medical stock include A Brett Murphy, Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz and Steven Payne. View Institutional Ownership Trends for Globus Medical. Which major investors are selling Globus Medical stock? GMED stock was sold by a variety of institutional investors in the last quarter, including NWQ Investment Management Company LLC, Prudential Financial Inc., Dimensional Fund Advisors LP, TIAA CREF Investment Management LLC, Victory Capital Management Inc., United Services Automobile Association, AXA and Oak Ridge Investments LLC. Company insiders that have sold Globus Medical company stock in the last year include Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz and Steven Payne. View Insider Buying and Selling for Globus Medical. Which major investors are buying Globus Medical stock? GMED stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., AQR Capital Management LLC, Wells Fargo & Company MN, Broadview Advisors LLC, Nordea Investment Management AB, Canada Pension Plan Investment Board, Man Group plc and Bellevue Group AG. View Insider Buying and Selling for Globus Medical. How do I buy shares of Globus Medical? Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Globus Medical's stock price today? One share of GMED stock can currently be purchased for approximately $50.33. How big of a company is Globus Medical? Globus Medical has a market capitalization of $5.10 billion and generates $635.98 million in revenue each year. The medical device company earns $107.34 million in net income (profit) each year or $1.31 on an earnings per share basis. Globus Medical employs 1,500 workers across the globe. What is Globus Medical's official website? The official website for Globus Medical is http://www.globusmedical.com. How can I contact Globus Medical? Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected] MarketBeat Community Rating for Globus Medical (NYSE GMED)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 392 (Vote Outperform)Underperform Votes: 331 (Vote Underperform)Total Votes: 723MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/20/2018 by MarketBeat.com StaffFeatured Article: What is an Initial Public Offering (IPO)?